354 related articles for article (PubMed ID: 23978414)
1. Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease.
Li L; Hai J; Li Z; Zhang Y; Peng H; Li K; Weng X
Food Chem Toxicol; 2014 Jan; 63():166-73. PubMed ID: 23978414
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation.
Andrade JM; Paraíso AF; de Oliveira MV; Martins AM; Neto JF; Guimarães AL; de Paula AM; Qureshi M; Santos SH
Nutrition; 2014; 30(7-8):915-9. PubMed ID: 24985011
[TBL] [Abstract][Full Text] [Related]
3. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol prevents suppression of regulatory T-cell production, oxidative stress, and inflammation of mice prone or resistant to high-fat diet-induced obesity.
Wang B; Sun J; Li X; Zhou Q; Bai J; Shi Y; Le G
Nutr Res; 2013 Nov; 33(11):971-81. PubMed ID: 24176237
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy.
Ji G; Wang Y; Deng Y; Li X; Jiang Z
Lipids Health Dis; 2015 Oct; 14():134. PubMed ID: 26498332
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats.
Zhao JS; Zhu FS; Liu S; Yang CQ; Chen XM
Chin Med J (Engl); 2012 Jul; 125(13):2316-21. PubMed ID: 22882855
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol induces nuclear factor-κB activity in human cardiac cells.
Palomer X; Capdevila-Busquets E; Alvarez-Guardia D; Barroso E; Pallàs M; Camins A; Davidson MM; Planavila A; Villarroya F; Vázquez-Carrera M
Int J Cardiol; 2013 Sep; 167(6):2507-16. PubMed ID: 22748497
[TBL] [Abstract][Full Text] [Related]
9. Acetyl-L-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease.
Kathirvel E; Morgan K; French SW; Morgan TR
Nutr Res; 2013 Nov; 33(11):932-41. PubMed ID: 24176233
[TBL] [Abstract][Full Text] [Related]
10. Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A.
Jung TW; Youn BS; Choi HY; Lee SY; Hong HC; Yang SJ; Yoo HJ; Kim BH; Baik SH; Choi KM
Biochem Pharmacol; 2013 Oct; 86(7):960-9. PubMed ID: 23948064
[TBL] [Abstract][Full Text] [Related]
11. Alpha-lipoic acid attenuates methionine choline deficient diet-induced steatohepatitis in C57BL/6 mice.
Min AK; Kim MK; Kim HS; Seo HY; Lee KU; Kim JG; Park KG; Lee IK
Life Sci; 2012 Jan; 90(5-6):200-5. PubMed ID: 22154902
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression.
Abd El-Haleim EA; Bahgat AK; Saleh S
World J Gastroenterol; 2016 Mar; 22(10):2931-48. PubMed ID: 26973390
[TBL] [Abstract][Full Text] [Related]
13. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
Faghihzadeh F; Adibi P; Hekmatdoost A
Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory effects of total alkaloids from Rubus alceifolius Poir [corrected]. on non-alcoholic fatty liver disease through regulation of the NF-κB pathway.
Zhao J; Zheng H; Liu Y; Lin J; Zhong X; Xu W; Hong Z; Peng J
Int J Mol Med; 2013 Apr; 31(4):931-7. PubMed ID: 23426790
[TBL] [Abstract][Full Text] [Related]
15. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
16. Voluntary oral feeding of rats not requiring a very high fat diet is a clinically relevant animal model of non-alcoholic fatty liver disease (NAFLD).
Tipoe GL; Ho CT; Liong EC; Leung TM; Lau TY; Fung ML; Nanji AA
Histol Histopathol; 2009 Sep; 24(9):1161-9. PubMed ID: 19609863
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of interleukin-17 attenuates high fat diet-induced non-alcoholic fatty liver disease in mice.
Xu R; Tao A; Zhang S; Zhang M
Acta Biochim Biophys Sin (Shanghai); 2013 Sep; 45(9):726-33. PubMed ID: 23786840
[TBL] [Abstract][Full Text] [Related]
18. Carnosic acid protects mice from high-fat diet-induced NAFLD by regulating MARCKS.
Song HM; Li X; Liu YY; Lu WP; Cui ZH; Zhou L; Yao D; Zhang HM
Int J Mol Med; 2018 Jul; 42(1):193-207. PubMed ID: 29620148
[TBL] [Abstract][Full Text] [Related]
19. Role of immunodeficient animal models in the development of fructose induced NAFLD.
Bhattacharjee J; Kumar JM; Arindkar S; Das B; Pramod U; Juyal RC; Majumdar SS; Nagarajan P
J Nutr Biochem; 2014 Feb; 25(2):219-26. PubMed ID: 24445047
[TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways.
Xiao J; Ho CT; Liong EC; Nanji AA; Leung TM; Lau TY; Fung ML; Tipoe GL
Eur J Nutr; 2014 Feb; 53(1):187-99. PubMed ID: 23515587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
